

Key Sanochemia Group Data

in T€

	Q1	Q2	Q1-Q2	Q1-Q2	Change as %	2007/08	2006/07
	2008/09	2008/09	2008/09	2007/08		2007/08	2006/07
	Oct.08-Dec.08	Jan.09-Mar.09	Oct.08-Mar.09	Oct.07-Mar.08	Oct.07-Sep.08	Oct.06-Sep.07	
Sales revenues	5,950	7,972	13,922	12,440	12%	29,531	29,634
Sales&Marketing (Human Pharmaceuticals)	4,097	4,240	8,337	6,948	20%	14,787	12,731
Production	1,820	3,704	5,524	5,456	1%	12,605	16,849
R&D	33	28	61	36	69%	2,139	53
Reconciliation	0	0	0	0	0%	0	1
EBITDA	-1,810	314	-1,496	-655	-128%	3,667	-1,808
Depreciation / amortisation	-1,225	-1,248	-2,473	-2,364	-5%	-4,892	-3,693
EBIT	-3,035	-934	-3,969	-3,019	-31%	-1,225	-5,501
Sales&Marketing (Human Pharmaceuticals)	538	485	1,023	831	23%	2,223	1,713
Production	-1,940	119	-1,821	-835	-118%	-321	2,212
R&D	-468	-502	-970	-1,032	6%	-258	-5,056
Reconciliation	-1,165	-1,036	-2,201	-1,983	-11%	-2,869	-4,370
Financial result	20	-163	-143	-1,415	90%	-2,799	497
Pre-tax profit / loss	-3,015	-1,097	-4,112	-4,434	7%	-4,024	-5,004
Net profit / loss	-3,017	-1,097	-4,114	-4,534	9%	-3,709	-5,006
Earnings / losses per share	-0.29	-0.1	-0.39	-0.43	9%	-0.34	-0.44

	Q2	Q2	Change as %	2007/08	2006/07
	2008/09	2007/08		2007/08	2006/07
	31.03.2009	31.03.2008	30.09.2008	30.09.2007	
Balance sheet total	83,935	101,785	-18%	88,868	97,846
Tangible assets	17,323	17,783	-3%	17,799	17,634
Intangible assets	22,324	22,190	1%	21,956	23,218
Shareholders' equity	49,986	53,536	-7%	54,109	57,919
Equity ratio	59.6%	52.6%	13%	60.9%	59.2%

IFRS Cash flow

	Q1-Q2	Q1-Q2	Change as %	2007/08	2006/07
	2008/09	2007/08		2007/08	2006/07
	Oct.08-Mar.09	Oct.07-Mar.08	Oct.07-Sep.08	Oct.06-Sep.07	
Cash flow from operating activities	-2,417	-9,942	76%	-5,039	8,384
Cash flow from investment activity	2,409	-1,556		-3,375	-7,684
Cash flow from financing activity	-475	697		-1,618	2,143

Some minor changes may be due to rounding cumulative figures.